Intra-Cellular Therapies Reports Successful Outcome in Study 502 for Major Depressive Disorder
Tuesday, 18 June 2024, 12:09
Intra-Cellular Therapies: Positive Outcome in Lumateperone Study 502
In a recent development, Intra-Cellular Therapies, Inc. (ITCI) revealed encouraging results from Study 502, focusing on the efficacy of Lumateperone for Major Depressive Disorder (MDD).
Promising Results in Phase 3 Trial
- Positive Outcome: Lumateperone successfully met the primary endpoint in the clinical trial.
- Effective Treatment: The findings suggest potential benefits of Lumateperone in managing MDD symptoms.
This breakthrough underscores the significance of continued research and development in the field of mental health, offering hope for improved therapeutic options for individuals affected by MDD.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.